From Nasdaq: 2025-06-16 18:21:00

Novo Nordisk (NYSE: NVO) stock took a hit after a rival, Eli Lilly, announced plans to offer higher dosages of its weight-loss drug Zepbound, directly competing with Novo Nordisk’s Wegovy. Analyst Richard Vosser also cut Novo Nordisk’s price target, causing shares to drop by 3.5% on Monday. Despite the negative news, investors did not panic sell, indicating confidence in Wegovy’s potential. However, with Eli Lilly expanding its offerings, Novo Nordisk may face increased competition in the weight-loss drug market. Consider other investment options as Novo Nordisk may face challenges ahead.



Read more at Nasdaq: Why Novo Nordisk Stock Sank by Nearly 4% Today